DOP2009000270A - Antagonistas ciclicos de peptido cxcr4 - Google Patents

Antagonistas ciclicos de peptido cxcr4

Info

Publication number
DOP2009000270A
DOP2009000270A DO2009000270A DO2009000270A DOP2009000270A DO P2009000270 A DOP2009000270 A DO P2009000270A DO 2009000270 A DO2009000270 A DO 2009000270A DO 2009000270 A DO2009000270 A DO 2009000270A DO P2009000270 A DOP2009000270 A DO P2009000270A
Authority
DO
Dominican Republic
Prior art keywords
cxcr4
peptide antagonists
cycle peptide
cycle
antagonists
Prior art date
Application number
DO2009000270A
Other languages
English (en)
Spanish (es)
Inventor
Liang Zeng Yan
Wayne David Kohn
Sheng-Bin Peng
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39831600&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2009000270(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2009000270A publication Critical patent/DOP2009000270A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DO2009000270A 2007-05-30 2009-11-27 Antagonistas ciclicos de peptido cxcr4 DOP2009000270A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94080207P 2007-05-30 2007-05-30
US94099607P 2007-05-31 2007-05-31

Publications (1)

Publication Number Publication Date
DOP2009000270A true DOP2009000270A (es) 2010-01-15

Family

ID=39831600

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2009000270A DOP2009000270A (es) 2007-05-30 2009-11-27 Antagonistas ciclicos de peptido cxcr4

Country Status (32)

Country Link
US (3) US7691813B2 (enExample)
EP (2) EP2160221B1 (enExample)
JP (1) JP5358564B2 (enExample)
KR (2) KR101169846B1 (enExample)
CN (1) CN101678213B (enExample)
AR (1) AR066648A1 (enExample)
AT (1) ATE516853T1 (enExample)
AU (1) AU2008260326B2 (enExample)
BR (1) BRPI0812134A2 (enExample)
CA (1) CA2688574C (enExample)
CL (1) CL2008001467A1 (enExample)
CO (1) CO6241137A2 (enExample)
CR (1) CR11105A (enExample)
CY (1) CY1111815T1 (enExample)
DK (1) DK2160221T3 (enExample)
DO (1) DOP2009000270A (enExample)
EA (1) EA017716B1 (enExample)
GT (1) GT200900304A (enExample)
HR (1) HRP20110551T1 (enExample)
IL (1) IL201685A (enExample)
JO (1) JO2776B1 (enExample)
MA (1) MA31666B1 (enExample)
MX (1) MX2009012952A (enExample)
MY (1) MY149432A (enExample)
NZ (1) NZ580849A (enExample)
PE (1) PE20090299A1 (enExample)
PL (1) PL2160221T3 (enExample)
PT (1) PT2160221E (enExample)
TN (1) TN2009000496A1 (enExample)
TW (1) TWI423987B (enExample)
WO (1) WO2008150689A1 (enExample)
ZA (1) ZA200908345B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2942798B1 (fr) * 2009-03-05 2011-04-08 Centre Nat Rech Scient Peptides utilisables pour le traitement de la leucemie lymphoide chronique
IT1397901B1 (it) * 2010-01-26 2013-02-04 Consiglio Nazionale Ricerche Peptidi ciclici che legano il recettore cxcr4 e relativi usi in campo medico e diagnostico.
WO2012118124A1 (ja) * 2011-03-01 2012-09-07 国立大学法人京都大学 新規ケモカイン受容体拮抗剤
MX343205B (es) * 2011-06-07 2016-10-28 Polyphor Ag Peptidomiméticos de horquilla beta como antagonistas de cxc4.
WO2013044500A1 (zh) * 2011-09-30 2013-04-04 Cheng Yun 丙型肝炎病毒免疫原性肽或其衍生物在预防或治疗关节炎中的应用
CA2852160A1 (en) 2011-10-28 2013-05-02 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
EP2979991A1 (en) 2014-07-31 2016-02-03 Greif International Holding BV. Multilayer material, fire protection mat with said multilayer material and transport and storage container assembly comprising said fire protection mat.
ES2764840T3 (es) 2015-01-28 2020-06-04 Univ Bordeaux Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica
WO2017176565A1 (en) 2016-04-07 2017-10-12 Eli Lilly And Company Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
EP3509612A4 (en) * 2016-09-06 2021-07-21 Mainline Biosciences CXCR4 ANTAGONISTS AND METHOD OF USE
CN106841624B (zh) * 2017-01-26 2019-02-22 庄磊靓 抗人cd4和抗人cd184单克隆抗体作为标志物的应用
KR20200043970A (ko) * 2017-09-05 2020-04-28 메인라인 바이오사이언스 고친화성 cxcr4 선택적 결합 콘쥬게이트 및 그 사용 방법
US11123437B2 (en) * 2017-09-05 2021-09-21 Mainline Biosciences, Inc. Selective CXCR4 binding peptide conjugate and methods for making and using the same
US11771736B2 (en) * 2017-12-21 2023-10-03 Mainline Biosciences (Shanghai) Co., Ltd. Composition comprising a therapeutic agent and a CXCR4 selective antagonist and methods for using the same
JP2021165234A (ja) * 2018-07-03 2021-10-14 富士フイルム富山化学株式会社 Ｃｘｃｒ４結合性化合物もしくはその塩またはそれらと金属との錯体
EP3849997B1 (en) 2018-09-12 2024-05-01 Technische Universität München Cxcr4-targeted diagnostic and therapeutic agents with reduced species selectivity
EA202190755A1 (ru) 2018-09-12 2021-06-11 Технише Универзитет Мюнхен Агенты для терапии и диагностики рака
WO2020210919A1 (en) * 2019-04-18 2020-10-22 Provincial Health Services Authority Novel radiolabelled cxcr4-targeting compounds for diagnosis and therapy
EP4097120A4 (en) * 2020-01-26 2024-05-01 Mainline Biosciences (Shanghai) Co., Ltd. ISOTOPE-LABELED CXCR4 SELECTIVELY BINDING PEPTIDE CONJUGATE AND METHODS OF MAKING AND USE THEREOF
WO2022082312A1 (en) * 2020-10-21 2022-04-28 Provincial Health Services Authority Novel cxcr4-targeting compounds
CN116615411A (zh) * 2020-12-25 2023-08-18 中外制药株式会社 包含n-取代氨基酸残基的肽化合物的制造方法
WO2022138891A1 (ja) * 2020-12-25 2022-06-30 中外製薬株式会社 Ｎ－置換－アミノ酸残基を含むペプチド化合物の製造方法
EP4043041A1 (en) 2021-02-15 2022-08-17 Technische Universität München Cxcr4-ligands for diagnostic and therapeutic use and precursors thereof
JP2025513489A (ja) * 2022-04-20 2025-04-24 プロビンシャル・ヘルス・サービシーズ・オーソリティ Ｃｘｃｒ４標的化合物、およびその作製方法、およびその使用方法
CN115060901A (zh) * 2022-06-21 2022-09-16 中国医学科学院基础医学研究所 苹果酸酶2在制备矽肺病或肺纤维化相关疾病诊断试剂或治疗药物中的应用
WO2025218761A1 (zh) * 2024-04-17 2025-10-23 晶核生物医药科技(上海)有限公司 环状肽类化合物、其药物组合物及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4391123B2 (ja) * 2002-10-24 2009-12-24 株式会社オーファンリンク 新規ｃｘｃｒ４アンタゴニスト
US8628750B2 (en) * 2006-02-27 2014-01-14 Technische Universitat Munchen Cancer imaging and treatment

Also Published As

Publication number Publication date
KR20100003737A (ko) 2010-01-11
ZA200908345B (en) 2011-02-23
EP2160221A1 (en) 2010-03-10
CA2688574C (en) 2014-02-18
TN2009000496A1 (en) 2011-03-31
USRE42274E1 (en) 2011-04-05
GT200900304A (es) 2011-11-09
CN101678213A (zh) 2010-03-24
MY149432A (en) 2013-08-30
EP2160221B1 (en) 2011-07-20
CL2008001467A1 (es) 2008-12-05
AU2008260326B2 (en) 2011-07-21
TW200902556A (en) 2009-01-16
CO6241137A2 (es) 2011-01-20
CN101678213B (zh) 2013-11-06
US20100130409A1 (en) 2010-05-27
US7691813B2 (en) 2010-04-06
WO2008150689A1 (en) 2008-12-11
AR066648A1 (es) 2009-09-02
BRPI0812134A2 (pt) 2014-11-18
CR11105A (es) 2010-04-12
EA017716B1 (ru) 2013-02-28
EA200971129A1 (ru) 2010-04-30
PE20090299A1 (es) 2009-03-19
TWI423987B (zh) 2014-01-21
KR20110134519A (ko) 2011-12-14
HK1141474A1 (en) 2010-11-12
ATE516853T1 (de) 2011-08-15
US20080300177A1 (en) 2008-12-04
CY1111815T1 (el) 2015-10-07
JP2010529957A (ja) 2010-09-02
KR101319740B1 (ko) 2013-10-17
JP5358564B2 (ja) 2013-12-04
KR101169846B1 (ko) 2012-08-01
AU2008260326A1 (en) 2008-12-11
NZ580849A (en) 2012-03-30
MA31666B1 (fr) 2010-09-01
CA2688574A1 (en) 2008-12-11
IL201685A (en) 2015-04-30
IL201685A0 (en) 2010-05-31
HRP20110551T1 (hr) 2011-09-30
JO2776B1 (en) 2014-03-15
PT2160221E (pt) 2011-09-12
PL2160221T3 (pl) 2011-12-30
DK2160221T3 (da) 2011-09-19
EP2377579A1 (en) 2011-10-19
MX2009012952A (es) 2009-12-11

Similar Documents

Publication Publication Date Title
DOP2009000270A (es) Antagonistas ciclicos de peptido cxcr4
CY1111767T1 (el) Υδρογονωμενα παραγωγα βενζο[c]θειοφαινιου ως ανοσορρυθμιστες
CY1121658T1 (el) Πεπτιδια και χρηση αυτων
NO20073244L (no) Konjugeringsprodukt
CY1119243T1 (el) Φαρμακοτεχνικες μορφες ανταγωνιστη του vegf
CL2007002327A1 (es) Compuestos derivados de fenil-imidazol sustituido; composicion farmaceutica; y uso en el tratamiento del vhc.
BRPI0608087A2 (pt) formulações injetáveis e em aerossol de benzodiazepina em nanopartìculas
BR112012017345A2 (pt) "composições e métodos de pgl para a produção aumentada de isopreno e outros produtos com 6-fosfogliconolactonase (pgl)"
CL2008000751A1 (es) Compuestos derivados de cicloprop[d]indolo[2,1-a][2]benzacepina sustituidos con heterociclos; composicion farmaceutica; y uso en el tratamiento de infeccion por hepatitis c.
EA201390233A1 (ru) Фармацевтические композиции
MXPA06003474A (es) Agonistas de receptores de melanocortina.
CY1110170T1 (el) Ν-καρβαμοϋλμεθυλ-4(-r)-φαινυλ-2-πυρρολιδινονη, μεθοδος παρασκευης της και φαρμακευτικη χρηση αυτης
PE20120425A1 (es) Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga
CL2008002411A1 (es) Compuestos derivados de heterociclos de nitrogenos;composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la miosina del musculo liso o la miosina no muscular, tales como hipertension, enfermedad pulmonar, glaucoma, apoplejia, enfermedades broncocontrictoras, entre otras.
CL2008002689A1 (es) Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia.
ES2530670T3 (es) Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
CR20110202A (es) Antagonistas de la via hedgehog de ftalazina disustituida
CL2009000119A1 (es) Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
CL2007002671A1 (es) Compuestos derivados de octahidro-pirrolo[3,4-c]pirrol; composicion farmaceutica que la comprende; y uso del compuesto en el tratamiento del vih, sida o arc.
ATE514765T1 (de) Azeotropartige zusammensetzungen mit 1,1,1,2,3,3- hexafluor-3-methoxypropan und 1-brompropan
UY28282A1 (es) Mediadores peptidicos del trasporte inverso de colesterol para el tratamiento de hipercolesterolemia
EP2614075A4 (en) UNILATED RELAXIN POLYPEPTIDES
CL2008002223A1 (es) Compuestos derivados de 9-desoxo-9a-metil-9a-aza-9a-homoeritromicina a 2'-o-sustituida; proceso de preparación; compuesto intermediario; composición farmacéutica; y su uso en el tratamiento y/o profilaxis de la malaria.
ECSP109771A (es) Antagonistas cíclicos de péptido cxcr4
CL2010001589A1 (es) Compuestos derivados de 3-ciano-pirrolidin-fenil-oxazolidinonas; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de infecciones bacterianas.